Luise Linsenmeier

Luise Linsenmeier

Auto-generated profile, based on publicly available information

Luise Linsenmeier

Institute of Neuropathology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
LLLuise Linsenmeier
Luise Linsenmeier
HAHermann Altmeppen
Hermann Altmeppen
SWSebastian Wetzel
Sebastian Wetzel
BMBehnam Mohammadi
Behnam Mohammadi
PSPaul Saftig
Paul Saftig
MGMarkus Glatzel
Markus Glatzel

26 November 2021 in Science Advances
Verified
Journal Article
Open access
LLLuise Linsenmeier
Luise Linsenmeier
BMBehnam Mohammadi
Behnam Mohammadi
MSMohsin Shafiq
Mohsin Shafiq
KFKarl Frontzek
Karl Frontzek
JBJulia Bär
Julia Bär
MGMarkus Glatzel
Markus Glatzel
Ligand-stimulated enzymatic release or cellular degradation of PrP may interfere with neurodegeneration-associated toxicity.

4 May 2020 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
BMBehnam Mohammadi
Behnam Mohammadi
LLLuise Linsenmeier
Luise Linsenmeier
MSMohsin Shafiq
Mohsin Shafiq
Berta PuigBerta Puig
Berta Puig
GGGiovanna Galliciotti
Giovanna Galliciotti
HAHermann Altmeppen
Hermann Altmeppen
The structurally disordered N-terminal half of the prion protein (PrPC) is constitutively released into the extracellular space by an endogenous proteolytic cleavage event. Once liberated, this N1 fragment acts neuroprotective in ischemic conditions and interferes with toxic peptides associated with neurodegenerative diseases, such as amyloid-beta (Aβ) in Alzheimer’s disease. Since analog protective effects of N1 in prion diseases, such as Creutzfeldt-Jakob disease, have not been studied, and given that the protease releasing N1 has not been identified to date, we have generated and characterized transgenic mice overexpressing N1 (TgN1). Upon intracerebral inoculation of TgN1 mice with prions, no protective effects were observed at the levels of survival, clinical course, neuropathological, or molecular assessment. Likewise, primary neurons of these mice did not show protection against Aβ toxicity. Our biochemical and morphological analyses revealed that this lack of protective effects is seemingly due to an impaired ER translocation of the disordered N1 resulting in its cytosolic retention with an uncleaved signal peptide. Thus, TgN1 mice represent the first animal model to prove the inefficient ER translocation of intrinsically disordered domains (IDD). In contrast to earlier studies, our data challenge roles of cytoplasmic N1 as a cell penetrating peptide or as a potent “anti-prion” agent. Lastly, our study highlights both the importance of structured domains in the nascent chain for proteins to be translocated and aspects to be considered when devising novel N1-based therapeutic approaches against neurodegenerative diseases.

4 July 2015 in Prion
Verified
Journal Article
Open access
MGMarkus Glatzel
Markus Glatzel
LLLuise Linsenmeier
Luise Linsenmeier
FDFrank Dohler
Frank Dohler
SKSusanne Krasemann
Susanne Krasemann
Berta PuigBerta Puig
Berta Puig
HAHermann Altmeppen
Hermann Altmeppen
Proteolytic processing regulates key processes in health and disease. The cellular prion protein (PrPC) is subject to at least 3 cleavage events, α-cleavage, β-cleavage and shedding. In contrast to α- and β-cleavage where there is an ongoing controversy on the identity of relevant proteases, the metalloprotease ADAM10 represents the only relevant PrP sheddase. Here we focus on the roles that ADAM10-mediated shedding of PrPC and its pathogenic isoform (PrPSc) might play in regulating their physiological and pathogenic functions, respectively. As revealed by our recent study using conditional ADAM10 knockout mice (Altmeppen et al., 2015 Altmeppen HC , Prox J , Krasemann S , Puig B , Kruszewski K , Dohler F , Bernreuther C , Hoxha A , Linsenmeier L , Sikorska B , et al. The sheddase ADAM10 is a potent modulator of prion disease. eLife 2015; 4; PMID:25654651; doi:10.7554/eLife.04260 [Crossref], [PubMed], [Web of Science ®] [Google Scholar] ), shedding of PrP seems to be involved in key processes of prion diseases. These aspects and several open questions arising from them are discussed. Increased knowledge on this topic can shed new light on prion diseases and other neurodegenerative conditions as well.